IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of Approval

IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma.

Study finds higher levels of lncRNAs in the testes than previously estimated

Researchers at the University of Toronto have mapped the spatial distribution of around 700 long non-coding RNAs, otherwise known as lncRNAs, in the testes.

July 30, 2024

Mesoblast plans new GvHD trial after another FDA rejection – Pharmaceutical Technology

The news has led to a sharp 63.9% decline in market price of Mesoblast at market open today, compared to market close yesterday. Credit: khaleddesigner

August 4, 2023

Private Medicare plans collect billions for care veterans are actually getting from VA

One ad shows two older men talking jovially on a front porch, “Vietnam veteran” visible on one of their hats. Another shows an older man

November 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.